Search research articles
Contact Us
Filters
Showing results (271-280 of 315) with videos related to
Page
of 32
Sort By:
Journal of the American Academy of Dermatology
|
May 16, 2025
Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study
Lawrence F Eichenfield, Linda F Stein Gold, Eric L Simpson, et al.
Journal of the American Academy of Dermatology
|
May 22, 2024
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials
Jonathan I Silverberg, Lawrence F Eichenfield, Adelaide A Hebert, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
May 14, 2023
Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity From the Atopic Dermatitis Research Network (ADRN) Registry
Eric L Simpson, Anna De Benedetto, Mark Boguniewicz, et al.
Journal of the American Academy of Dermatology
|
December 15, 2022
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort
Katrina Abuabara, Lawrence F Eichenfield, Robert Bissonnette, et al.
The British Journal of Dermatology
|
January 23, 2025
Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS)
Jonathan I Silverberg, Lawrence F Eichenfield, Andrew Blauvelt, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
November 9, 2020
Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials
Jonathan I Silverberg, Eric L Simpson, Emma Guttman-Yassky, et al.
Dermatology and Therapy
|
May 2, 2024
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
Eric L Simpson, Vimal H Prajapati, Yael A Leshem, et al.
American Journal of Clinical Dermatology
|
December 12, 2019
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
Amy S Paller, Ashish Bansal, Eric L Simpson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 13, 2023
Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis
Yael Renert-Yuval, Ester Del Duca, Bernd Arents, et al.
The Journal of Allergy and Clinical Immunology
|
September 29, 2024
CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity
H Mark Kenney, Takeshi Yoshida, Evgeny Berdyshev, et al.
Page
of 32
Search research articles
Search
Showing results (271-280 of 315) with videos related to
Sort By:
Page
of 32
Journal of the American Academy of Dermatology
|
May 16, 2025
Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study
Lawrence F Eichenfield, Linda F Stein Gold, Eric L Simpson, et al.
Journal of the American Academy of Dermatology
|
May 22, 2024
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials
Jonathan I Silverberg, Lawrence F Eichenfield, Adelaide A Hebert, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
May 14, 2023
Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity From the Atopic Dermatitis Research Network (ADRN) Registry
Eric L Simpson, Anna De Benedetto, Mark Boguniewicz, et al.
Journal of the American Academy of Dermatology
|
December 15, 2022
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort
Katrina Abuabara, Lawrence F Eichenfield, Robert Bissonnette, et al.
The British Journal of Dermatology
|
January 23, 2025
Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS)
Jonathan I Silverberg, Lawrence F Eichenfield, Andrew Blauvelt, et al.
Dermatitis : Contact, Atopic, Occupational, Drug
|
November 9, 2020
Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials
Jonathan I Silverberg, Eric L Simpson, Emma Guttman-Yassky, et al.
Dermatology and Therapy
|
May 2, 2024
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
Eric L Simpson, Vimal H Prajapati, Yael A Leshem, et al.
American Journal of Clinical Dermatology
|
December 12, 2019
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
Amy S Paller, Ashish Bansal, Eric L Simpson, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 13, 2023
Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis
Yael Renert-Yuval, Ester Del Duca, Bernd Arents, et al.
The Journal of Allergy and Clinical Immunology
|
September 29, 2024
CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity
H Mark Kenney, Takeshi Yoshida, Evgeny Berdyshev, et al.
Page
of 32